Updated:
Blue Ocean Ventures
Blue Ocean Ventures was co-founded in Geneva by Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz and Thomas Zehnder — four operators who each built and...
Blue Ocean Ventures
Blue Ocean Ventures was co-founded in Geneva by Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz and Thomas Zehnder — four operators who each built and sold healthcare or technology companies before pooling their networks into a dedicated early-stage fund. The group met through shared advisory roles inside Innosuisse, the Swiss Confederation's innovation agency, and structured the firm as a Jersey-registered Limited Partnership in a jurisdiction chosen deliberately for its investor-friendly treatment. The firm concentrates on pre-investment-ready medical device and diagnostics startups across Switzerland and Europe, typically entering at first-round valuations of CHF 3 million to CHF 10 million. It maintains a secondary mandate in digital health, life sciences and nanotechnologies. Blue Ocean acts as both lead investor and co-investor alongside larger venture firms; its Limited Partners — exclusively family offices and high-net-worth individuals — gain contractual co-investment rights. Known portfolio positions include Abionic (rapid-diagnostics platform), DistalMotion (robotic surgery), Rheon Medical (adjustable glaucoma shunts) and Volumina Medical (soft-tissue reconstruction), all commercializing research that originated inside the Swiss Federal Institutes of Technology ecosystem. The team draws on a scientific advisory board anchored by ETH Lausanne professor Nikos Stergiopulos — a serial inventor with over 200 publications and 20 patents — and deploys deal-sourcing relationships with FONGIT (Geneva's premier incubator), the Swiss Private Equity & Corporate Finance Association, and the patent law firm P&TS. In December 2023, Blue Ocean disclosed a Jersey-based administrative footprint through Ocorian for its fund vehicle, reinforcing a two-jurisdiction structure that separates advisory activities in Switzerland from fund governance in the Channel Islands. What separates Blue Ocean from generalist Swiss venture managers is its institutionalized right-of-first-look arrangement: the founders sit inside the federal grant-making apparatus itself — de Watteville remains Head of Startup Financing at FONGIT while managing the fund — creating a sourcing advantage that functions more like a government-adjacent technology-transfer office than a conventional venture firm. The succession model is deliberately collective; no single founder controls investment decisions, and the partnership agreement distributes authority across all four advisors, none of whom carry a traditional GP title on the firm's own materials.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Geneva
Corporate office
34 route de la Galaise, CH-1228 Geneva, Switzerland
Additional offices
St Helier, Jersey
Principals
Faris Sabeti
Advisor and Co-Founder
Emmanuel de Watteville
Advisor and Co-Founder
Sacha Haymoz
Advisor
Thomas Zehnder
Advisor
Sector focus
Frequently asked questions
Who runs investment decisions at Blue Ocean Ventures?
The four co-founders — Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz and Thomas Zehnder — share investment authority collectively. The firm does not designate a single managing partner or CIO on its public materials; instead it operates through advisor-level consensus, with de Watteville maintaining a parallel role as Head of Startup Financing at Geneva's FONGIT incubator, which gives him direct line-of-sight into pre-incorporation teams.
How does Blue Ocean Ventures source proprietary deal flow?
Through embedded access to the Swiss federal innovation pipeline. The founders sit inside Innosuisse (the Swiss Confederation's Innovation Promotion Agency) as evaluators and coaches — de Watteville alone has reviewed over 200 high-tech startups through FONGIT and the former CTI program. This positions Blue Ocean to identify companies before they become investment-ready, often 12 to 24 months ahead of a formal funding round.
Is Blue Ocean Ventures structured as a single family office?
No. Blue Ocean is a Jersey-registered Limited Partnership fund that pools capital from multiple family offices and high-net-worth individuals. It is not tied to any single family's wealth and operates as a conventional early-stage venture firm with a specialized medical-device mandate.
Does Blue Ocean Ventures participate in fund commitments or only direct deals?
Blue Ocean executes only direct investments into portfolio companies. The firm acts as either lead investor on rounds or as a syndicated co-investor alongside reputed venture capital firms — the website states explicitly that LPs receive co-investment rights under certain conditions, but there is no fund-of-funds activity.
What investment stages does Blue Ocean Ventures typically target?
The firm concentrates on pre-investment-ready startups and first institutional rounds, with pre-money valuations typically between CHF 3 million and CHF 10 million. It monitors promising companies before they are ready for external capital, then organizes the first round. Blue Ocean typically requires a board seat and reserves capital for follow-on rounds.
How is Blue Ocean Ventures related to FONGIT?
Emmanuel de Watteville serves simultaneously as Co-Founder and Advisor at Blue Ocean Ventures and as Head of Startup Financing at FONGIT, Geneva's primary technology incubator. This dual role creates a direct pipeline from FONGIT's resident companies into Blue Ocean's deal flow, though the two entities are legally separate.
Where does Blue Ocean Ventures' deal flow for companies like Rheon Medical originate?
Much of the portfolio traces back to the Swiss Federal Institutes of Technology. Nikos Stergiopulos, a Blue Ocean Scientific Advisor and EPFL professor, co-founded Rheon Medical (adjustable glaucoma shunts) directly from his laboratory. Similarly, Volumina Medical and Abionic originated from EPFL and ETH Zurich research programs, reflecting the fund's systematic reliance on federal academic research as its primary deal engine.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: